Kawasaki disease: high-dose Aspirin is associated with anemia and does not confer benefit to disease outcomes
Kawasaki disease ( KD ) is also known as multiple mucocutaneous lymph node syndrome of systemic vasculitis and is a leading cause of coronary artery lesions ( CAL ) in childhood.
Intravenous immunoglobulin ( IVIG ) has been proven to effectively reduce the incidence of coronary artery lesions, but the role and effect dose of Aspirin [ Acetylsalicylic acid ] in Kawasaki disease is still unclear.
Moreover, overt bleeding and anemia are associated with the use of Aspirin, and anemia is common in patients with Kawasaki disease.
The aim of a study was conducted to compare the treatment efficacy, degree of anemia and inflammation, and changes in serum hepcidin in children who received a combination of high-dose Aspirin and IVIG in the acute stage of Kawasaki disease, and those who received IVIG alone.
Patients with Kawasaki disease from two medical centers were retrospectively analyzed from 1999-2009.
All patients were initially treated with a single dose of IVIG ( 2 g/kg ) as the standard care of treatment.
In group 1, high-dose Aspirin was prescribed ( more than 30 mg/kg/day ) until the fever subsided, and then low-dose Aspirin ( 3-5 mg/kg/day ) was prescribed until all the inflammation signs had resolved.
In group 2, low-dose Aspirin was prescribed without high-dose Aspirin.
A total of 851 patients with Kawasaki disease ( group 1, N = 305, group 2, N = 546 ) were enrolled in this study. There were no significant differences between group 1 and group 2 in terms of gender ( p = 0.51 ), IVIG resistance rate ( 31/305 vs 38/546, p = 0.07 ), coronary artery lesions formation ( 52/305 vs. 84/546, p = 0.67 ), and duration of hospitalization ( 6.3 ± 0.2 vs. 6.7 ± 0.2 days, p = 0.13 ).
There were also initially no significant differences in total white blood cell count, hemoglobin level, platelet count, and CRP before IVIG treatment between groups ( all p less than 0.1 ).
After IVIG treatment, group 1 had significantly lower levels of hemoglobin ( p = 0.006 ) and higher CRP ( p less than 0.001 ) as well as a smaller decrease in CRP level ( p = 0.012 ).
Furthermore, there was also a higher serum level of hepcidin and a delayed decrease in hepcidin level after receiving IVIG in group 1 ( p = 0.04 and 0.02, respectively ).
In conclusion, these results provide evidence demonstrating that high-dose Aspirin in the acute phase of Kawasaki disease does not confer any benefit with regards to inflammation and it does not appear to improve treatment outcomes.
Therefore, high-dose Aspirin is unnecessary in acute phase Kawasaki disease. ( Xagena )
Kuo HC et al, PLoS One 2015;10(12):e0144603. doi: 10.1371/journal.pone.0144603. eCollection 2015.
Real-world ACS population: Ticagrelor doesn’t lessen risks of myocardial infarction or death and may increase bleeding relative to Clopidogrel
Major bleeding after acute coronary syndrome predicts a poor outcome but is challenging to define. The choice of antiplatelet influences...
Changes in the lung microbiome may help predict how well critically ill patients will respond to care. Specifically, patients with higher...
Diabetic patients with COVID-19, characteristics and outcome: a two-centre, retrospective, case control study
Since December 2019, a pneumonia caused by SARS-CoV-2 which was later named as COVID-19 emerged and many people lost...
Coronavirus disease 2019 ( COVID-19 ) is a pandemic with no specific therapeutic agents and substantial mortality. It is...
SARS-CoV-2 uses the angiotensin-converting enzyme ( ACE ) 2 receptor for entry into target cells. ACE2 is predominantly expressed by...
Initial preliminary findings from the Papa Giovanni XXIII Hospital sponsored SISCO ( Siltuximab In Serious COVID-19 ) Study, based on...
ESC 2019 - ENTRUST-AF PCI trial: Edoxaban dual therapy noninferior to triple therapy in atrial fibrillation post-stenting
Edoxaban ( Lixiana ) in combination with a P2Y12 inhibitor is noninferior to standard triple therapy for preventing bleeding in...
FDA has approved treatment for patients with endometrial carcinoma: Lenvima in combination with Keytruda
The FDA ( U.S. Food and Drug Administration ) has announced Project Orbis, an initiative of the FDA Oncology Center...
A study has evaluated the efficacy and tolerability of intravenous Lacosamide ( LCM-iv ) under routine conditions in daily clinical...